Bringing up palliative care is inherently difficult for providers, because it means bringing up death and dying, said Toby C. Campbell, MD, MSCI, associate professor of medicine, hematology-oncology at the University of Wisconsin School of Medicine and Public Health.
Bringing up palliative care is inherently difficult for providers, because it means bringing up death and dying, said Toby C. Campbell, MD, MSCI, associate professor of medicine, hematology-oncology at the University of Wisconsin School of Medicine and Public Health and chief of Palliative Care and program director of the Hospice and Palliative Medicine Fellowship Training Program.
Transcript (slightly modified)
How difficult is it for healthcare providers to bring up the topic of palliative care?
Talking about palliative care means acknowledging someone’s mortality. It means, by some measure, beginning to talk about an incurable disease, beginning to talk about dying. And so I think it is inherently difficult.
I want to make clear, though, that patients are already worried about it. From the very beginning when they hear the word “cancer,” they’re already scared. They’re already worried; their minds have already gone to the question “Is this going to take my life? Am I going to die?” So this won’t be the first time that they’ve brought it up. But for many patients and families they will not bring it up without some prompting from the oncologist.
And so what we have learned in survey data and other places is that patients and families want to talk about this—in fact, they expect to talk about it. But they, generally speaking, won’t bring it up themselves. So it is important actually for the oncologist to be comfortable with bringing this up, be willing to bring it up, to talk both about palliative care but also about life expectancy, about what happens when you’re dealing with an advanced cancer.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More